One important strategy for improving antitumor immunity and overcoming these self-tolerance mechanisms is vaccination with peptide variants of TAAs (also known as mimotopes, heteroclitic peptides, peptide analogues, or altered peptide ligands) that improve binding to either MHC molecules [4] or tumor-specific T cell receptor (TCR) molecules [5, 6]. Here, HLA-C is linked to neoplasm.